The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 10, 2021

Filed:

Aug. 01, 2019
Applicant:

Mercator Medsystems, Inc., Emeryville, CA (US);

Inventor:

Kirk Patrick Seward, San Francisco, CA (US);

Assignee:

MERCATOR MEDSYSTEMS, INC., Emeryville, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/19 (2006.01); A61M 25/10 (2013.01); A61K 31/155 (2006.01); A61K 31/395 (2006.01); A61K 45/06 (2006.01); A61M 25/00 (2006.01); A61K 9/00 (2006.01); A61M 5/00 (2006.01); A61M 5/44 (2006.01);
U.S. Cl.
CPC ...
A61M 25/1002 (2013.01); A61K 9/0019 (2013.01); A61K 31/155 (2013.01); A61K 31/395 (2013.01); A61K 45/06 (2013.01); A61M 5/00 (2013.01); A61M 5/007 (2013.01); A61M 5/44 (2013.01); A61M 25/00 (2013.01); A61M 25/0084 (2013.01); A61M 2025/009 (2013.01);
Abstract

Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or sympathetic nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.


Find Patent Forward Citations

Loading…